T1	Participants 114 136	stage III colon cancer
T2	Participants 492 571	patients with stage III colon cancer who enrolled in a phase III clinical trial
T3	Participants 1019 1235	432 (15.2%) blood samples and 143 (14.6%) tumor samples heterozygous or homozygous for the LCS6 G-allele, and 2,402 of 2,834 (84.8%) blood samples and 834 of 977 (85.4%) tumor samples homozygous for the LCS6 T-allele
